Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Subscribe To Our Newsletter & Stay Updated
